RU2016129069A - Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты - Google Patents
Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты Download PDFInfo
- Publication number
- RU2016129069A RU2016129069A RU2016129069A RU2016129069A RU2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A RU 2016129069 A RU2016129069 A RU 2016129069A
- Authority
- RU
- Russia
- Prior art keywords
- alginic acid
- mannuronate
- contraceptive
- guluronate
- residues
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 16
- 239000000783 alginic acid Substances 0.000 title claims 11
- 235000010443 alginic acid Nutrition 0.000 title claims 11
- 229920000615 alginic acid Polymers 0.000 title claims 11
- 229960001126 alginic acid Drugs 0.000 title claims 11
- 150000004781 alginic acids Chemical class 0.000 title claims 11
- 239000000203 mixture Substances 0.000 title claims 9
- 150000001875 compounds Chemical class 0.000 title claims 5
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000003377 anti-microbal effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims 6
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims 5
- 230000000844 anti-bacterial effect Effects 0.000 claims 5
- 239000003433 contraceptive agent Substances 0.000 claims 5
- 230000002254 contraceptive effect Effects 0.000 claims 5
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims 4
- 239000000227 bioadhesive Substances 0.000 claims 4
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 125000005614 guluronate group Chemical group 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
- A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/065—Condom-like devices worn by females
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Способ предотвращения зачатия или снижения риска распространения заболеваний, передающихся половым путем, включающий местное введение контрацептивной бактерицидной композиции, содержащей около 1-10% альгиновой кислоты, около 1-10% биоадгезивного соединения и около 1-10% L-молочной кислоты;
при этом альгиновая кислота имеет соотношение остатков маннуроната : гулуроната в дипазоне от 0,25 до 2,0, и композиция находится в нематричном состоянии, когда не контактирует с эякулятом, и в матричном состоянии, когда контактирует с эякулятом.
2. Способ по п. 1, в котором альгиновая кислота имеет среднюю молекулярную массу от около 20000 до около 400000.
3. Способ по п. 1, в котором альгиновая кислота имеет среднюю молекулярную массу от около 75000 до около 375000.
4. Способ по п. 1, в котором альгиновая кислота имеет молекулярную массу от 100000 до 200000.
5. Способ по п. 1, в котором соотношение остатков маннуроната:гулуроната составляет от 0,2 до 0,45.
6. Способ по п. 5, в котором соотношение остатков маннуроната:гулуроната составляет от 0,3 до 0,45.
7. Способ по п. 6, в котором соотношение остатков маннуроната:гулуроната составляет от 0,35 до 0,45.
8. Способ по п. 1, в котором контрацептивная бактерицидная композиция содержит около 3-5% альгиновой кислоты, около 2,5-6% биоадгезивного соединения и около 1-7% L-молочной кислоты.
9. Способ по любому из пп. 1-8, в котором биоадгезивное соединение выбрано из группы, состоящей из: ксантановой камеди, альгиновой кислоты, гидроксипропилцеллюлозы, гидроксипропилметилцеллюлозы, натрий-карбоксиметалцеллюлозы, хитозана, поликарбофила и карбопола.
10. Способ по любому из пп. 1-8, в котором контрацептивная бактерицидная композиция имеет рН между около 3 и около 4.
11. Способ по любому из пп. 1-8, в котором контрацептивная бактерицидная композиция имеет рН между около 3,5 и около 4,5.
12. Способ предотвращения зачатия или снижения риска распространения заболеваний, передающихся половым путем, включающий местное введение контрацептивной бактерицидной композиции, содержащей около 1-10% альгиновой кислоты, около 1-10% биоадгезивного соединения и около 1-10% L-молочной кислоты, при этом альгиновая кислота имеет соотношение остатков маннуроната:гулуроната в дипазоне от 0,2 до 0,4.
13. Способ по п. 12, в котором альгиновая кислота имеет молекулярную массу от 20000 до 400000.
14. Способ по любому из пп. 1-8, 12-13, в котором композиция дополнительно содержит фармацевтически приемлемый носитель.
15. Способ по п. 14, в котором композиция дополнительно содержит фармацевтически приемлемый носитель на водной основе.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918445P | 2013-12-19 | 2013-12-19 | |
| US61/918,445 | 2013-12-19 | ||
| PCT/US2014/071664 WO2015095793A1 (en) | 2013-12-19 | 2014-12-19 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016129069A true RU2016129069A (ru) | 2018-01-23 |
| RU2691950C1 RU2691950C1 (ru) | 2019-06-19 |
Family
ID=53403777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016129069A RU2691950C1 (ru) | 2013-12-19 | 2014-12-19 | Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11337989B2 (ru) |
| EP (2) | EP3082826B1 (ru) |
| JP (3) | JP2017501227A (ru) |
| KR (1) | KR102407408B1 (ru) |
| CN (2) | CN114452298A (ru) |
| AU (2) | AU2014368971B2 (ru) |
| BR (1) | BR112016014506B1 (ru) |
| DK (1) | DK3082826T3 (ru) |
| ES (1) | ES2790703T3 (ru) |
| IL (1) | IL246146B2 (ru) |
| MX (2) | MX2016008023A (ru) |
| NZ (1) | NZ722215A (ru) |
| RU (1) | RU2691950C1 (ru) |
| WO (1) | WO2015095793A1 (ru) |
| ZA (1) | ZA201604862B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201408243VA (en) | 2012-06-13 | 2015-01-29 | Evofem Inc | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| JP2017501227A (ja) | 2013-12-19 | 2017-01-12 | エヴォフェム，インク． | アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 |
| DE102017110168A1 (de) | 2016-05-25 | 2017-11-30 | Samsung Electronics Co., Ltd. | Elektronische Vorrichtung mit NFC-Antenne |
| WO2018049326A1 (en) * | 2016-09-12 | 2018-03-15 | Evofem Biosciences, Inc. | Combination gel for sexually transmitted infections |
| EP3522879A4 (en) * | 2016-10-04 | 2020-06-03 | Evofem, Inc. | METHOD OF TREATING AND PREVENTING BACTERIAL VAGINOSIS |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1213323B (it) | 1986-08-07 | 1989-12-20 | Crinos Industria Farmaco | Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida |
| US4999342A (en) | 1988-08-16 | 1991-03-12 | Ortho Pharmaceutical Corporation | Long lasting contraceptive suppository composition and methods of use |
| JP3202365B2 (ja) * | 1992-12-04 | 2001-08-27 | 株式会社紀文フードケミファ | オリゴマンヌロン酸を重合度によって分離する方法 |
| US5592949A (en) | 1994-06-29 | 1997-01-14 | Moench; Thomas R. | Device for acidic buffering and method for inactivation of pathogens |
| US5667492A (en) | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
| FR2728464B1 (fr) | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
| US6093394A (en) | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
| AU1661901A (en) | 1999-11-24 | 2001-06-04 | Cargill Dow Llc | Improved lactic acid processing; methods; arrangements; and, products |
| CN100488517C (zh) * | 2000-03-07 | 2009-05-20 | 拉什-长老会-圣路加医学中心 | 捕获和灭活病原性微生物和精子的组合物及其制药用途 |
| JP2009102407A (ja) * | 2001-03-08 | 2009-05-14 | Rohto Pharmaceut Co Ltd | Ｇリッチなアルギン酸含有組成物 |
| US20020177624A1 (en) | 2001-03-16 | 2002-11-28 | Calvin Hanna | Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis |
| ITMI20010913A1 (it) | 2001-05-04 | 2002-11-04 | Univ Pavia | Composizioni a rilascio controllato di acido lattico a livello vaginale |
| EP1399151A4 (en) * | 2001-06-11 | 2004-08-04 | Merck & Co Inc | PROCESS FOR THE TREATMENT OF INFLAMMATORY DISEASES BY ADMINISTRATION OF A PPAR-DELTA AGONIST |
| US20130150810A1 (en) | 2002-04-30 | 2013-06-13 | The Population Council, Inc. | Intravaginal ring for the delivery of unique combinations of antimicrobial compositions |
| AU2003252694A1 (en) * | 2002-07-26 | 2004-02-16 | Mikasa Seiyaku Co., Ltd. | External preparation |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| WO2004110461A1 (en) | 2003-06-13 | 2004-12-23 | Idh Holding Aps | Treatment of symptoms associated with bacterial vaginosis |
| US20050272700A1 (en) | 2004-05-10 | 2005-12-08 | Servet Buyuktimkin | Topical treatment and prevention of human papilloma virus (HPV) infection |
| RU2257197C1 (ru) * | 2004-05-12 | 2005-07-27 | Дулькис Мария Дмитриевна | Вагинальные суппозитории, обладающие контрацептивным действием |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| BRPI0718707A2 (pt) * | 2006-11-10 | 2014-01-07 | Rohto Pharma | Composição para aplicação em pele ou em mucosa |
| US7659259B2 (en) * | 2006-12-21 | 2010-02-09 | Bausch & Lomb Incorporated | Method of treating inflammation of the eye |
| MX2009010445A (es) | 2007-03-30 | 2010-01-29 | Laccure Ab | Uso de oligomeros de acido lactico en el tratamiento de trastornos ginecologicos. |
| WO2008148018A2 (en) | 2007-05-24 | 2008-12-04 | New York Blood Center Inc. | Rapidly dispersible vaginal tablet that provides a bioadhesive gel |
| TW200927141A (en) | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
| CA2721457A1 (en) | 2008-04-16 | 2009-10-22 | Cipla Limited | Topical combinations comprising an antimycotic agent and an antiviral agent |
| WO2009155118A1 (en) | 2008-05-30 | 2009-12-23 | Reprotect, Inc. | Compositions and methods for inactivation of pathogens at genital tract surfaces |
| EP2130531A1 (en) | 2008-06-04 | 2009-12-09 | Rolf Kullgren AB | Vaginal suppository comprising lactic acid |
| WO2010142761A1 (en) | 2009-06-10 | 2010-12-16 | Ultimorphix Technologies B.V. | The succinate of tenofovir disoproxil |
| AR086249A1 (es) * | 2011-05-02 | 2013-11-27 | Aptalis Pharmatech Inc | Composiciones de tabletas de disolucion rapida de administracion vaginal |
| CN103763925A (zh) | 2011-06-28 | 2014-04-30 | 梅迪奇制药有限公司 | 高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途 |
| SG11201408243VA (en) | 2012-06-13 | 2015-01-29 | Evofem Inc | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| WO2015027071A1 (en) | 2013-08-21 | 2015-02-26 | Georgia Regents Research Institute, Inc. | Gpr81 agonists and methods thereof for promoting production of secretory iga |
| JP2017501227A (ja) | 2013-12-19 | 2017-01-12 | エヴォフェム，インク． | アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 |
| AU2015201042A1 (en) | 2014-02-28 | 2015-09-17 | Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd | Therapeutic Method |
-
2014
- 2014-12-19 JP JP2016560871A patent/JP2017501227A/ja active Pending
- 2014-12-19 NZ NZ722215A patent/NZ722215A/en unknown
- 2014-12-19 EP EP14871611.1A patent/EP3082826B1/en active Active
- 2014-12-19 AU AU2014368971A patent/AU2014368971B2/en active Active
- 2014-12-19 ES ES14871611T patent/ES2790703T3/es active Active
- 2014-12-19 EP EP20161479.9A patent/EP3735966A1/en not_active Withdrawn
- 2014-12-19 RU RU2016129069A patent/RU2691950C1/ru active
- 2014-12-19 BR BR112016014506-2A patent/BR112016014506B1/pt active IP Right Grant
- 2014-12-19 KR KR1020167019494A patent/KR102407408B1/ko active IP Right Grant
- 2014-12-19 US US15/106,755 patent/US11337989B2/en active Active
- 2014-12-19 MX MX2016008023A patent/MX2016008023A/es unknown
- 2014-12-19 IL IL246146A patent/IL246146B2/en unknown
- 2014-12-19 DK DK14871611.1T patent/DK3082826T3/da active
- 2014-12-19 CN CN202210078304.4A patent/CN114452298A/zh active Pending
- 2014-12-19 WO PCT/US2014/071664 patent/WO2015095793A1/en active Application Filing
- 2014-12-19 CN CN201480075975.9A patent/CN106029078A/zh active Pending
-
2016
- 2016-06-17 MX MX2021001742A patent/MX2021001742A/es unknown
- 2016-07-14 ZA ZA2016/04862A patent/ZA201604862B/en unknown
-
2020
- 2020-03-31 JP JP2020063444A patent/JP2020125298A/ja active Pending
- 2020-04-29 AU AU2020202835A patent/AU2020202835B2/en active Active
-
2022
- 2022-02-07 JP JP2022017393A patent/JP2022070924A/ja active Pending
- 2022-04-19 US US17/724,378 patent/US20220241301A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201604862B (en) | 2017-08-30 |
| AU2014368971B2 (en) | 2020-02-06 |
| IL246146B2 (en) | 2024-03-01 |
| CN114452298A (zh) | 2022-05-10 |
| AU2020202835B2 (en) | 2021-12-02 |
| EP3082826B1 (en) | 2020-03-11 |
| BR112016014506A2 (pt) | 2017-10-31 |
| ES2790703T3 (es) | 2020-10-28 |
| RU2691950C1 (ru) | 2019-06-19 |
| CN106029078A (zh) | 2016-10-12 |
| US20220241301A1 (en) | 2022-08-04 |
| MX2016008023A (es) | 2017-01-13 |
| JP2022070924A (ja) | 2022-05-13 |
| US11337989B2 (en) | 2022-05-24 |
| IL246146B1 (en) | 2023-11-01 |
| JP2020125298A (ja) | 2020-08-20 |
| WO2015095793A1 (en) | 2015-06-25 |
| BR112016014506B1 (pt) | 2022-06-28 |
| KR20160103036A (ko) | 2016-08-31 |
| KR102407408B1 (ko) | 2022-06-10 |
| EP3735966A1 (en) | 2020-11-11 |
| JP2017501227A (ja) | 2017-01-12 |
| AU2020202835A1 (en) | 2020-05-21 |
| IL246146A0 (en) | 2016-07-31 |
| AU2014368971A1 (en) | 2016-07-28 |
| MX2021001742A (es) | 2021-04-19 |
| NZ722215A (en) | 2019-02-22 |
| EP3082826A1 (en) | 2016-10-26 |
| EP3082826A4 (en) | 2017-08-23 |
| US20160354394A1 (en) | 2016-12-08 |
| DK3082826T3 (da) | 2020-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016129069A (ru) | Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| UA105766C2 (ru) | Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин | |
| WO2014186742A3 (en) | Anhydrous hydrogel composition | |
| BR112012024683A2 (pt) | preparado sólido facilmente dosável | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| AR080735A1 (es) | Una composicion farmaceutica de disolucion rapida | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| WO2015075745A3 (en) | Turmeric extract containing soft pastilles | |
| BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
| WO2011070318A3 (en) | Topical formulation | |
| WO2011112922A3 (en) | Co-crystals and pharmaceutical formulations comprising the same | |
| MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
| JP6646390B2 (ja) | 外用組成物 | |
| AR075274A1 (es) | Agente de tratamiento de semillas y metodo para proteger una planta | |
| RU2014142066A (ru) | Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения | |
| JP2017501227A5 (ru) | ||
| RU2016131211A (ru) | Комбинированный лекарственный препарат для профилактики инфекций, передающихся половым путём | |
| JP2013521297A5 (ru) | ||
| JP2015528515A5 (ru) | ||
| WO2014178789A9 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| JP2015519395A5 (ru) | ||
| UA118581C2 (uk) | Зволожувальні агенти | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов |